Open AccessCoffee C21 and protection of DNA from strand breaks: evaluation of a health claim pursuant to Article 13(5) of Regulation ( EC ) No 1924/2006
Author(s) -
Turck Dominique,
Castenmiller Jacqueline,
De Henauw Stefaan,
Ildico HirschErnst Karen,
Kearney John,
Knutsen Helle Katrine,
Maciuk Alexandre,
Mangelsdorf Inge,
McArdle Harry J,
Naska Androniki,
Pelaez Carmen,
Pentieva Kristina,
Thies Frank,
Tsabouri Sophia,
Vinceti Marco,
Bresson JeanLouis,
Siani Alfonso
Publication year - 2020
Publication title -
efsa journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.076
H-Index - 97
ISSN - 1831-4732
DOI - 10.2903/j.efsa.2020.6055
Subject(s) - trigonelline , health claims on food labels , authorization , health benefits , food allergens , human health , food science , toxicology , microbiology and biotechnology , biology , environmental health , traditional medicine , medicine , genetics , immunoglobulin e , computer security , computer science , antibody
Abstract Following an application from Tchibo GmbH submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation ( EC ) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Nutrition, Novel Foods and Food Allergens ( NDA ) was asked to deliver an opinion on the scientific substantiation of a health claim related to Coffee C21 and protection of DNA from strand breaks. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The food proposed by the applicant as the subject of the health claim is Coffee C21. The Panel considers that Coffee C21, a coffee standardised by its concentration of caffeoylquinic acids ( CQA ), trigonelline and N ‐methylpyridinium ( NMP ), is sufficiently characterised in relation to the claimed effect. The Panel considers that the claimed effect, protection of DNA from strand breaks, is a beneficial physiological effect. Out of the two human intervention studies from which conclusion could be drawn, one study provides some evidence that daily consumption of Coffee C21 (750 mL /day) for 4 weeks decreases DNA strand breaks in habitual coffee drinkers after coffee withdrawal over the previous four weeks. However, the results of this study were not replicated in another study conducted under similar conditions in the same study centre. No studies performed in a different setting, from which conclusions could be drawn, were available. No evidence has been provided for a mechanism by which coffee (including Coffee C21) would reduce DNA damage in human cells by reducing DNA strand breaks. The Panel concludes that a cause and effect relationship has not been established between the consumption of Coffee C21 and protection of DNA from strand breaks.